Key Data:
Location
Utsunomiya, Japan
Estimated investment
¥14.96 billion
Completion
Phase one Q1 2003, Phase two Q2 2005, Phase three 2008
Start of operations
Phase one Q1 2004, Phase two Q2 2006, Phase three 2008+
Output chemicals
Monoclonal antibodies and recombinant proteins
Plant capacity
80,000L following phase two but will expand to in excess of 90,000L
Key Players:
Sponsor
Chugai Pharmaceutical Co. Ltd
Lead engineer / designer
Hitachi Ltd
Validation
Hitachi Ltd, Amersham Biosciences (Fast Track)